The National Blood Authority (NBA) has commenced procurement activities for those Imported Plasma and Recombinant Products (IPRP) which have current supply arrangements scheduled to expire 30 June 2025.
The approach to market materials for an open tender for Recombinant Factor VIII (rFVIII) and Recombinant Factor IX (rFIX) products have now been published on AusTender(Opens in a new tab/window). The procurement approach for Emicizumab (Hemlibra) is a limited tender to a sole supplier.
Any further information in relation to these procurements prior to their finalisation will be published on AusTender(Opens in a new tab/window). For any specific queries for the NBA, please contact CBP.Procurement@blood.gov.au.
Last updated: 03 Dec 2024